Triomics operates at the intersection of generative AI and clinical oncology. Founded in 2021, the company has built a platform that processes longitudinal patient records to automate workflows across cancer centers. Its technology serves four of the top ten U.S. cancer centers, including Memorial Sloan Kettering, Yale Cancer Center, Mount Sinai, and Regenstrief/Indiana University Health, processing over 120,000 charts and screening more than 65,000 patients for clinical trials each month.
At the core of Triomics is OncoLLM, a specialized large language model that reasons across entire patient histories to deliver structured, cited answers with expert-level accuracy directly into electronic medical record workflows. The broader Triomics AI Platform automates patient trial matching, visit preparation, pre-charting, and cancer registry curation across NAACCR, SEER, COC, and QOPI measures.
The company has raised $37 million in funding and is headquartered in the United States. Its technical work spans large language models, natural language processing, and clinical data processing - applied specifically to oncology, a domain where accuracy and speed carry significant consequences for patient outcomes.
